Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  oncolytic virotherapy
Results 1-25 of 31 for your search:
Start Over
Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, KEYNOTE-034, 2014-000185-22, NCT02263508
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: JX594-HEP024, NCI-2016-00198, NCT02562755
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201504731, NCI-2015-01193, 20139075, NCT02453191
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
Talimogene Laherparepvec in Treating Patients with Recurrent Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0034, NCI-2016-00199, NCT02658812
Talimogene Laherparepvec and Radiation Therapy in Treating Patients with Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10056, NCI-2016-01461, MC1678, NCT02923778
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2401BT-002P, NCI-2016-01819, NCT02798406
Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1534, NCI-2017-00535, NCT03069378
Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0671, NCI-2009-01198, MAYO-MC0671, MAYO-06-004440, NCT00390299
Oncolytic HSV1716 in Treating Patients with Refractory Non-Central Nervous System Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 13 to 30
Trial IDs: OSU-08196, NCI-2016-00251, IRB13-00471, NCT00931931
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Recombinant Oncolytic Poliovirus PVS-RIPO in Treating Patients with Recurrent Grade IV Malignant Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00031169, NCI-2013-01899, PVSRIPO, NS20023, NCT01491893
Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, Mod1000260438, NCT01503177
Viral Therapy in Treating Patient with Refractory Liver Cancer or Advanced Solid Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1148, NCI-2012-00890, 11-007114, NCT01628640
Viral Therapy In Treating Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0979, NCI-2013-00811, NCT01846091
Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200)
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: VLA 009/ KEYNOTE-200, NCI-2016-01131, 2012-005256-42, NCT02043665
IL-12-Expressing HSV-1 in Treating Patients with Recurrent or Progressive Glioblastoma, Anaplastic Astrocytoma, or Gliosarcoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UAB1317, NCI-2016-01806, NCT02062827
Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: VLA013, NCI-2016-00732, PHS IRB: 14-241, NCT02307149
Wild-Type Reovirus in Combination with Sargramostim in Treating Younger Patients with High-Grade Relapsed or Refractory Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 10 to 21
Trial IDs: MC1472, NCI-2015-00665, NCT02444546
Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20140318, NCI-2015-02069, 2014-005386-67, NCT02509507
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16M-15-2, NCI-2015-01069, REO 019, NCT02514382
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1372, NCI-2016-00179, NCT02700230
Start Over